The first-in-man reported phase I trial of CAR-NK cells demonstrated the safety of irradiated CD33-CD28-4-1BB-CD3ζ CAR-NK-92 cells infusion in 3 patients with R/R AML, but it did not demonstrate obvious clinical efficacy [118]. Here, CD33 is linked to acute myeloid leukemia.